Q-omics provides the consensus-scored ARL4AP3 profile across patient tissues and cancer cell-line models. ARL4AP3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARL4AP3 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, ARL4AP3 RNA expression shows 8,555 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUSC, and LSCC as cancer lineages where ARL4AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL4AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL4AP3 survival associations across molecular data types. ARL4AP3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL4AP3 RNA expression–survival associations across cancer types. High ARL4AP3 expression shows unfavorable associations in ACC, MESO, STAD, CHOL and KIRP, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARL4AP3 RNA expression.
This table summarizes ARL4AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARL4AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL4AP3 shows lower tumor expression in CHOL and KICH and higher tumor expression in LUSC, ESCA, COAD and HNSC. The LUSC box plot shows higher ARL4AP3 RNA expression in tumor versus normal tissue (log2 FC = +0.188, t-test p = .016).
This table shows molecular features associated with ARL4AP3 in patient tissues and cancer cell lines. In patient samples, ARL4AP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
